News

The treatment candidate RXC007 demonstrated promising efficacy in easing fibrosis, or scarring, in mouse models of idiopathic pulmonary fibrosis (IPF) and other scarring-related conditions. In healthy human volunteers participating in a recently-completed Phase 1 trial, RXC007 displayed a good safety and pharmacological profile. Now, Redx Pharma, the company…

Dosing has begun in healthy volunteers in a Phase 1 clinical trial evaluating the safety and pharmacological properties of LASN01, an experimental therapy for pulmonary fibrosis and other diseases characterized by excessive tissue scarring, or fibrosis. “The initiation of this trial is an important milestone for Lassen and continues…

Bellerophon Therapeutics has gotten the green light to cut by about half the number of patients who may enter REBUILD, its ongoing Phase 3 trial of INOpulse (inhaled nitric oxide) for the treatment of pulmonary hypertension linked to pulmonary fibrosis. The downsizing may help the company complete the…

Piceatannol, a natural compound with antioxidant and anti-inflammatory properties, eased the signs and symptoms of pulmonary fibrosis (PF) in mice, a study reported. According to its researchers, these findings indicate that piceatannol could be a promising treatment candidate for PF. The study, “Piceatannol-mediated JAK2/STAT3 signaling pathway inhibition…

Algernon Pharmaceuticals has filed for orphan drug status for NP-120 (ifenprodil), an experimental oral medicine for patients with idiopathic pulmonary fibrosis (IPF) who have persistent, hard-to-treat cough. “The FDA has a standard response time of 90 days to requests for orphan designation, and so we should know by…

Treatment with Haduvio (nalbuphine extended-release tablets) significantly reduced coughing for people with idiopathic pulmonary fibrosis (IPF), according to top-line data from the Phase 2 CANAL trial. “It is very promising to see such a significant reduction in chronic cough in IPF patients with [Haduvio],” Peter Dicpinigaitis, MD, a professor…

A molecular test, called the Envisia Genomic Classifier, may predict which patients with idiopathic pulmonary fibrosis (IPF) will progress on immunosuppressants, which could help doctors decide who will more likely benefit from antifibrotic therapy. The test, developed by Veracyte, can tell IPF from other types of interstitial lung…

The oral anti-fibrotic treatment Ofev (nintedanib) was found to be generally well-tolerated among children and adolescents with fibrosing interstitial lung diseases (ILDs) in the Phase 3 InPedILD clinical trial. “Data from the InPedILD trial demonstrate that [Ofev] has an acceptable safety and tolerability profile in children and adolescents with…

Patients receiving a higher dose of PLN-74809 in the Phase 2a INTEGRIS-IPF clinical trial, which is testing the oral treatment candidate for idiopathic pulmonary fibrosis (IPF), are showing positive safety outcomes. That’s according to data from a safety review analysis conducted by the study’s data safety monitoring board (DSMB)…

NP-120 (ifenprodil), an investigational treatment for idiopathic pulmonary fibrosis (IPF) and chronic cough, continues to demonstrate an ability to preserve lung function and ease cough, according to analyses of secondary goals in a Phase 2a trial. Most of these analyses related to patient-reported outcomes, supplementing positive top-line data from…